Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

As converter technology improves, so does the demand to resolve very high intermediate frequencies (IFs) accurately at high speeds. This poses two challenges: the converter design itself and the front ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Protalix BioTherapeutics, Inc. (PLX) quant rating optimized for predictive value. Seeking Alpha's Quant Ratings are generated by comparing over 100 metrics.

Abstract: To minimize the mutual coupling between co-polarized aperture-coupled patch antennas used in full-duplex applications, a novel decoupling method is introduced. This method involves creating ...

Find the latest Protalix BioTherapeutics, Inc. (PLX) stock quote, history, news and other vital information to help you with your stock trading and investing.

Find out the direct holders, institutional holders and mutual fund holders for Protalix BioTherapeutics, Inc. (PLX).

Abstract: In this paper, an ultra-wideband, tightly coupled, reconfigurable transmitarray (UTRTA) with 50° beam scanning capability is proposed. The ultra-wideband performance of the array is improved ...